{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:39:13Z","timestamp":1791005953821,"version":"4.1.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Neurosci."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the safety and tolerability of intravitreal injection of human retinal progenitor cells (RPCs) at multiple dose levels in adults with non-syndromic retinitis pigmentosa (RP).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>A prospective, multicenter, open-label, single-arm, Phase I\/IIa safety study of RPCs in adults with RP (<jats:italic>n<\/jats:italic> = 28). Two patient cohorts were studied: Cohort 1: BCVA no better than 20\/200 and no worse than Hand Motions, and Cohort 2: BCVA no better than 20\/40 and no worse than 20\/200).<\/jats:p><\/jats:sec><jats:sec><jats:title>Subjects<\/jats:title><jats:p>Adults (<jats:italic>n<\/jats:italic> = 28) with a clinical diagnosis of RP confirmed by electroretinogram, consenting to gene mutation typing for genes involved in inherited retinal degenerations and related disorders, and willing to undergo human leukocyte antigen (HLA) typing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Subjects, who were not selected for genotype, were divided across the two vision cohorts with each receiving a single intravitreal injection of one of: 0.5, 1.0, 2.0, or 3.0 \u00d7 10<jats:sup>6<\/jats:sup> allogeneic RPCs. Initially, subjects received the lowest dose (0.5 \u00d7 10<jats:sup>6<\/jats:sup> RPCs) in the worse-seeing eye. Each dose group contained equal numbers of subjects from Cohorts 1 and 2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Intravitreal RPC injection was well tolerated and associated with mostly transient mild to moderate adverse events. There were no signs of graft rejection. While primarily a safety study, exploratory efficacy assessments suggested improved BCVA measurements at all doses, with a possible dose-response at the highest levels. Mean BCVA change from pre-treatment to Month 12 in the treated vs untreated eyes was 1.4 letters for the 0.5 \u00d7 10<jats:sup>6<\/jats:sup> dose group, 1.0 letters for the 1.0 \u00d7 10<jats:sup>6<\/jats:sup> group, 4.8 letters for the 2.0 \u00d7 10<jats:sup>6<\/jats:sup> group, and 9.0 letters for the 3.0 \u00d7 10<jats:sup>6<\/jats:sup> group. Additional patient-reported changes included increased light sensitivity, improved object recognition, color discrimination, and reading.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A single intravitreal injection of RPCs was well tolerated in this safety study. The exploratory efficacy data suggest potential improvement of BCVA in some RP patients, particularly at the highest dose. While viewed cautiously, the possible treatment effect should be further investigated in larger controlled studies. The RPC technology has received FDA Regenerative Medicine Advanced Therapy designation. Later phase studies are ongoing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:uri>https:\/\/clinicaltrials.gov\/study\/NCT02320812<\/jats:uri>, NCT02320812.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fncel.2025.1646156","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T05:25:26Z","timestamp":1756099526000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Retinal progenitor cells (jCell) for retinitis pigmentosa"],"prefix":"10.3389","volume":"19","author":[{"given":"Jing","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baruch D.","family":"Kuppermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitul C.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinhui","family":"Hsiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Menges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Klassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000435886","article-title":"Threshold levels of visual field and acuity loss related to significant decreases in the quality of life and emotional states of patients with retinitis pigmentosa.","volume":"54","author":"Azoulay","year":"2015","journal-title":"Opthalmic. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1172\/JCI132990","article-title":"Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase I trial.","volume":"130","author":"Campochiaro","year":"2020","journal-title":"J. Clin. Invest."},{"key":"B3","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/glia.21155","article-title":"GDNF-induced osteopontin from Muller glial cells promotes photoreceptor survival in the Pde6brd1 mouse model of retinal degeneration.","volume":"59","author":"Del Rio","year":"2011","journal-title":"Glia"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.neuron.2015.02.017","article-title":"Subtype-specific regeneration of retinal ganglion cells following axotomy: Effects of osteopontin and mTOR signaling.","volume":"85","author":"Duan","year":"2015","journal-title":"Neuron"},{"key":"B5","first-page":"1993","article-title":"Nonsyndromic retinitis pigmentosa overview","author":"Fahim","year":"2023","journal-title":"GeneReviews"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6288","DOI":"10.1038\/347083a0","article-title":"Photoreceptor degeneration in inherited retinal dystrophy delayed by basic fibroblast growth factor.","volume":"347","author":"Faktorovich","year":"1990","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.devbrainres.2004.06.014","article-title":"Identification of pleiotrophin in conditioned medium secreted from neural stem cells by SELDI-TOF and SELDI-tandem mass spectrometry.","volume":"152","author":"Furuta","year":"2004","journal-title":"Brain Res. Dev. Brain Res."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/13816810.2025.2482610","article-title":"Mesencephalic astrocyte-derived neurotrophic factor (MANF) up-regulates CHOP and ATF6 in the rat retina.","author":"Gao","year":"2025","journal-title":"Ophthalmic. Genet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1750-1172-1-40","article-title":"Retinitis pigmentosa.","volume":"1","author":"Hamel","year":"2006","journal-title":"Orphanet J. Rare Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1006\/bbrc.2001.4765","article-title":"Mechanisms of neuroprotection by a novel rescue factor humanin from Swedish mutant amyloid precursor protein.","volume":"283","author":"Hashimoto","year":"2001","journal-title":"Biochem. Biophys. Res. Comm."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1073\/pnas.95.6.3088","article-title":"Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or leber congenital amaurosis.","volume":"95","author":"Morimura","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B12","doi-asserted-by":"publisher","first-page":"6294","DOI":"10.1126\/science.aaf3646","article-title":"Immune modulation by MANF promotes tissue repair and regenerative success in the retina.","volume":"353","author":"Neves","year":"2016","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","first-page":"7481","DOI":"10.3390\/ijms24087481","article-title":"Retinitis pigmentosa: Current clinical management and emerging therapies.","volume":"24","author":"Nguyen","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2174\/1567201815666181031163111","article-title":"Humanin nanoparticles for reducing pathological factors characteristic of age-related macular degeneration.","volume":"16","author":"Solanki","year":"2019","journal-title":"Curr. Drug Delivery"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1167\/iovs.15-17053","article-title":"The mitochondrial-derived peptide humanin protects RPE cells from oxidative stress, senescence, and mitochondrial dysfunction.","volume":"57","author":"Sreekumar","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1073\/pnas.90.4.1526","article-title":"Pigment epithelium-derived factor: Neurotrophic activity and identification as a member of the serine protease inhibitor gene family.","volume":"90","author":"Steele","year":"1993","journal-title":"Proc. Nat. Acad. Sci. U S A."},{"key":"B17","first-page":"4063","article-title":"Rescue of photoreceptors from the damaging effects of constant light by midkine, a retinoic acid-responsive gene product.","volume":"35","author":"Unoki","year":"1994","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"8060","DOI":"10.3390\/ijms25158060","article-title":"Amelioration of photoreceptor degeneration by intravitreal transplantation of retinal progenitor cells in rats.","volume":"25","author":"Yang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"6655372","DOI":"10.1155\/2021\/6655372","article-title":"Age-related macular degeneration (AMD) transmitochondrial cybrids protected from cellular damage and death by human retinal progenitor cells (hRPCs).","volume":"2021","author":"Yu","year":"2021","journal-title":"Stem. Cells Int."}],"container-title":["Frontiers in Cellular Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fncel.2025.1646156\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T05:25:27Z","timestamp":1756099527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fncel.2025.1646156\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":19,"alternative-id":["10.3389\/fncel.2025.1646156"],"URL":"https:\/\/doi.org\/10.3389\/fncel.2025.1646156","relation":{},"ISSN":["1662-5102"],"issn-type":[{"value":"1662-5102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"article-number":"1646156"}}